JP6890540B2 - 肺高血圧症のための併用療法 - Google Patents

肺高血圧症のための併用療法 Download PDF

Info

Publication number
JP6890540B2
JP6890540B2 JP2017536934A JP2017536934A JP6890540B2 JP 6890540 B2 JP6890540 B2 JP 6890540B2 JP 2017536934 A JP2017536934 A JP 2017536934A JP 2017536934 A JP2017536934 A JP 2017536934A JP 6890540 B2 JP6890540 B2 JP 6890540B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
pulmonary
composition according
pah
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017536934A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502126A (ja
JP2018502126A5 (enExample
Inventor
レオ・グ
ポール・シー・ナカガキ
ナリンダー・エス・バネイト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivus LLC
Original Assignee
Vivus LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivus LLC filed Critical Vivus LLC
Publication of JP2018502126A publication Critical patent/JP2018502126A/ja
Publication of JP2018502126A5 publication Critical patent/JP2018502126A5/ja
Application granted granted Critical
Publication of JP6890540B2 publication Critical patent/JP6890540B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017536934A 2015-01-13 2016-01-08 肺高血圧症のための併用療法 Active JP6890540B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562103020P 2015-01-13 2015-01-13
US62/103,020 2015-01-13
PCT/US2016/012694 WO2016114993A1 (en) 2015-01-13 2016-01-08 Combination therapy for pulmonary hypertension

Publications (3)

Publication Number Publication Date
JP2018502126A JP2018502126A (ja) 2018-01-25
JP2018502126A5 JP2018502126A5 (enExample) 2019-02-21
JP6890540B2 true JP6890540B2 (ja) 2021-06-18

Family

ID=56406244

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017536934A Active JP6890540B2 (ja) 2015-01-13 2016-01-08 肺高血圧症のための併用療法

Country Status (12)

Country Link
US (4) US20180325875A1 (enExample)
EP (1) EP3244968B1 (enExample)
JP (1) JP6890540B2 (enExample)
KR (1) KR102569428B1 (enExample)
CN (1) CN107427698A (enExample)
AU (1) AU2016207046B2 (enExample)
BR (1) BR112017014914B1 (enExample)
CA (1) CA2973114C (enExample)
IL (1) IL253325A0 (enExample)
MX (1) MX2017009110A (enExample)
NZ (1) NZ733451A (enExample)
WO (1) WO2016114993A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
JP2019533713A (ja) * 2016-11-10 2019-11-21 アレーナ ファーマシューティカルズ，インク． ラリンパグと他の薬剤とを組み合わせた肺動脈高血圧症を処置する方法
CN110381951A (zh) * 2016-12-14 2019-10-25 瑞必治公司 用于治疗肺性高血压和其他肺病症的方法及组合物
CN112569357B (zh) * 2019-09-30 2023-03-28 深圳奥萨制药有限公司 双重内皮素受体拮抗剂与利尿剂的组合物
BR112022010311A2 (pt) 2019-11-29 2022-08-16 Actelion Pharmaceuticals Ltd Métodos de tratamento de hipertensão arterial pulmonar

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110171193A1 (en) * 2008-06-12 2011-07-14 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating pulmonary hypertension
PT3821891T (pt) * 2011-05-02 2023-08-31 Univ Leland Stanford Junior Utilização de fk506 para o tratamento da hipertensão arterial pulmonar
CN103814131A (zh) 2011-05-09 2014-05-21 格拉斯哥大学理事会 在肺动脉高血压的治疗中调控microrna的方法
WO2013142369A1 (en) * 2012-03-23 2013-09-26 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pulmonary hypertension with leukotriene inhibitors

Also Published As

Publication number Publication date
RU2017128481A3 (enExample) 2019-06-25
EP3244968B1 (en) 2023-08-30
KR20170103918A (ko) 2017-09-13
CN107427698A (zh) 2017-12-01
EP3244968A1 (en) 2017-11-22
BR112017014914B1 (pt) 2023-11-14
EP3244968A4 (en) 2018-09-12
CA2973114C (en) 2023-04-04
KR102569428B1 (ko) 2023-08-21
AU2016207046B2 (en) 2021-04-01
CA2973114A1 (en) 2016-07-21
US20200069658A1 (en) 2020-03-05
NZ733451A (en) 2023-02-24
US20210267951A1 (en) 2021-09-02
US20240238259A1 (en) 2024-07-18
WO2016114993A1 (en) 2016-07-21
BR112017014914A2 (pt) 2018-03-13
US20180325875A1 (en) 2018-11-15
JP2018502126A (ja) 2018-01-25
RU2017128481A (ru) 2019-02-14
AU2016207046A1 (en) 2017-07-27
MX2017009110A (es) 2017-11-09
IL253325A0 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
US20240238259A1 (en) Combination therapy for pulmonary hypertension
CA2669536C (en) Combinations of ambrisentan and pde5 inhibitors for treating pulmonary arterial hypertension
US20130225595A1 (en) Method for treating pulmonary arterial hypertension in a patient not having idiopathic pulmonary fibrosis
KR20150002876A (ko) 폐 고혈압 치료의 조성물 및 방법
US20210338642A1 (en) Compositions and methods for the treatment or prevention of pulmonary hypertension
JP2023541766A (ja) 慢性腎疾患の治療のためのジボテンタン及びダパグリフロジンの組み合わせ
WO2010062640A1 (en) Methods for treating idiopathic pulmonary fibrosis and associated complications
TW201215392A (en) Use of ranolazine for treating pulmonary hypertension
TW201302203A (zh) Ａ２b腺苷受體拮抗劑於在心肌梗塞後之病患內治療心衰竭及心律不整上之用途
JP2020520948A (ja) 心不全の治療用のホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）アゴニストの新規な使用
JP2025172745A (ja) 肺動脈性肺高血圧症の治療方法
RU2780758C2 (ru) Комбинированная терапия легочной гипертензии
JP2013526503A (ja) キサンチンオキシダーゼ阻害剤とアンジオテンシンｉｉ受容体アンタゴニストとの合剤およびその使用
US20070072848A1 (en) Combinations of at1-antagonists, amiloride or triamterine, and a diuretic
TWI900606B (zh) 用於治療內皮素相關疾病之齊泊騰坦和達格列淨的組合
JP2008533109A (ja) 利尿を促進するための複合治療

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210427

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210525

R150 Certificate of patent or registration of utility model

Ref document number: 6890540

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250